



HBM Biopharma Summit

22nd–24th September 2024
Park Hyatt Zurich

HBM Partners

HBM Healthcare
Investments



WELCOME

For more than a decade, HBM hosted yearly conferences, providing a meeting platform for industry professionals and investors to exchange views with experts and peers about the latest developments in the biopharma industry.

NETWORKING

With networking being a key element of the HBM Biopharma Summit, we have enough time reserved for you to interact with other participants.

EXPERT PANEL

Melanie Senior, Biopharma Reporter & Science Strategy Writer (moderator)

Interactive dialogue with Vlad Coric, Niels Emmerich, Richard Girling and Michal Preminger.

To the Event Website:



CONFERENCE PROGRAM

September 22

- 16:00 REGISTRATION & WELCOME DESK Ballroom Foyer
- 18:30 TRANSFER TO DINNER LOCATION Meet in Lobby
- 18:45 INFORMAL DINNER AT RESTAURANT SEEROSE
Restaurant Seerose, Seestrasse 493, 8038 Zürich
- 22:00 ONWARDS GROUP TRANSFERS TO PARK HYATT HOTEL

September 23 Ballroom Foyer & Ballroom

- 07:15 REGISTRATION & WELCOME COFFEE

COMPANY PRESENTATIONS

- | | | | |
|-------|--------------------|-------|----------------------|
| 07:45 | Ignis Therapeutics | 10:15 | Orano Med |
| 08:00 | Sobi | 10:30 | Sanofi |
| 08:15 | Abbvie | 10:45 | Chemomab |
| 08:30 | Dren Bio | 11:00 | Argenx |
| 08:45 | Royalty Pharma | 11:15 | ADARx |
| 09:00 | Johnson & Johnson | 11:30 | Neurelis |
| 09:15 | Numab Therapeutics | 11:45 | Alumis |
| 09:30 | Insmed | 12:00 | Odyssey Therapeutics |
| 09:45 | Biohaven | 12:15 | Arrakis |
| 10:00 | Zymeworks | | |

NETWORKING LUNCH

11:30 UNTIL 13:30

September 23 Ballroom

CONFERENCE

- 13:30 **Keynotes**
- David Redfern, GSK, President Corporate Development
 - Michel Lagarde, Thermo Fisher Scientific, Executive Vice President & Chief Operating Officer

New Frontiers in Next-Gen Cell Biology

Mostafa Ronaghi, Cellanome, Cofounder, Executive Chairman

Building the first Row Commercialization Platform for Biopharma

Jean-Michel Lespinasse, Swixx BioPharma, CEO

The Healthcare M&A Environment

Richard Girling, Centerview Partners, Partner

Panel

State of the Industry

Moderated by Melanie Senior, Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO

- 18:40 **SHORT WALK TO DINNER LOCATION**

Easy 15 minute walk along river and old town

- 19:00 **COCKTAILS & DINNER ZUNFTHAUS ZUR MEISEN**

Zunfthaus zur Meisen, Münsterhof 20, 8001 Zürich

- 22:00 **WALK BACK TO PARK HYATT HOTEL**

INFORMAL GATHERING IN ONYX BAR, PARK HYATT HOTEL

(please bring your conference badge to the bar)

September 24 Ballroom Foyer & Ballroom

07:15 COFFEE & CROISSANTS

COMPANY PRESENTATIONS

07:45	eGenesis	11:45	Y-mAbs Therapeutics
08:00	Karius	12:00	Aphaia
08:15	Fore Biotherapeutics	13:00	Biontech
08:30	Astellas	13:15	Perspective Therapeutics
08:45	Molecular Partners	13:30	Real Endpoints
09:00	Vicore Pharma	13:45	Traverse Therapeutics
09:15	Cellanome	14:00	Neuron23
09:45	ALX Oncology	14:15	Arcutis Biotherapeutics
10:00	Mineralys	14:30	Mahzi Therapeutics
10:15	Denali	14:45	Abivax
10:30	Nikang Therapeutics	15:00	MeiraGTx
10:45	Biomea Fusion	15:15	Basilea Pharmaceutica
11:00	Orna Therapeutics	15:30	TrueMed Therapeutics
11:15	Fangzhou	15:45	Atara Biotherapeutics
11:30	Monte Rosa Therapeutics	16:00	Shenzhen Chipscreen
		16:15	BioInvent

NETWORKING LUNCH

11:30 UNTIL 13:30

SPEAKERS



Please scan QR code for full bio and/or company website

DAVID REDFERN

President Corporate Development GSK

David was appointed President Corporate Development of GSK in May 2008 and is responsible for corporate development and the leadership of the execution of all GSK's business development activities. He is a member of the GSK Leadership Team and reports to the CEO. In addition to his current role, David is Chairman of ViiV Healthcare Ltd. ViiV was created in 2010 and is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the research, development and commercialisation of medicines to treat HIV and has global sales of £6billion.

MICHEL LAGARDE

Executive Vice President &
Chief Operating Officer Thermo Fisher Scientific

Michel was named Executive Vice President in September 2019 and became Chief Operating Officer in January 2022. Michel has responsibility for Thermo Fisher's Pharma Services, Customer Channels, BioProduction, Analytical Instruments and Clinical Research Groups, as well as the company's Corporate Accounts function and Chief Medical Office. He joined the company as Senior Vice President and President of the Pharma Services Group through the acquisition of Patheon in 2017.



Please scan QR code for full bio and/or company website

SPEAKERS



RICHARD GIRLING

Partner, Centerview Partners

Richard Girling is one of Europe's leading healthcare bankers with over 30 years of experience. Mr. Girling has advised on many of the largest global healthcare transactions including: AstraZeneca in its \$39bn acquisition of Alexion and its \$15bn acquisition of MedImmune, Sanofi's \$73bn acquisition of Aventis and its \$1.9bn acquisition of Kadmon, the \$24bn LBO of Alliance Boots plc and its subsequent \$27bn sale to Walgreens and Vifor Pharma on its \$12bn sale to CSL. Mr. Girling established the European business of Centerview Partners in London in 2009. Since the creation of the Healthcare practice at Centerview Partners, the Healthcare team has advised on a number of significant transactions.



Please scan QR code for full bio and/or company website

JEAN-MICHEL LESPINASSE

Chief Executive Officer, Swixx Biopharma

Jean-Michel Lespinasse is the CEO of Swixx Biopharma, a leading pharmaceutical agent specializing in Rare Diseases, Oncology, Hematology, Vaccines, and Specialty Pharmaceuticals. Since the company's inception in 2015, Jean-Michel has grown Swixx into an organization of over 1,500 employees and 1,1 Billion Euros net sales, with a presence spanning from Central and Eastern Europe, to CIS, and Middle East. Under his leadership, in June 2024, Swixx successfully acquired Biopas in Latin America, further expanding its global footprint.



Please scan QR code for full bio and/or company website



MOSTAFA RONAGHI

Co-Founder and Executive Board Member Cellanome

Dr. Ronaghi is a scientist-entrepreneur, inventor, investor, company-founder, executive and director. He is the co-founder and executive Board Member at Cellanome. Most recently, he was Chief Executive Officer at Dynamics Special Purpose Corp, a SPAC company that acquired Senti Bio. Prior to that, he was Chief Technology Officer, Senior Vice President and member of the Executive Leadership Team at Illumina (Nasdaq: ILMN) from 2008 to 2021. While at Illumina, in 2016, Dr. Ronaghi co-founded GRAIL, a next-gen liquid biopsy platform for cancer detection. He also started Illumina's Research & Technology Development group, and co-founded the Illumina Accelerator Program in 2014, one of the most successful accelerator programs in the industry. Prior to Illumina, Dr. Ronaghi was Principal Investigator at the Stanford Genome Technology Center from 1999 to 2008.



Please scan QR code for full bio and/or company website

MELANIE SENIOR

Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO. Science strategy writer for biopharma firms

I write about biopharma R&D, strategy, investment and market access for the Nature portfolio, Evaluate Pharma and Celine. I also support companies and associations with market positioning and white papers. My career began at the London Financial Times; I then became Bureau Chief, Europe, for Elsevier Business Intelligence. I worked as a reimbursement and pricing analyst for Real Endpoints in the US and was part of EY Life Sciences' thought leadership team between 2014-2017. My education includes a First Class degree in Natural Sciences (biochemistry) from Cambridge University and post-graduate qualifications in Sports Physiology & Nutrition (St Mary's University) and in International Health Technology Assessment (University of Sheffield). I'm a keen runner, cyclist and swimmer (but not a triathlete). At the moment, I'm based in London, UK.



Please scan QR code for full bio and/or company website

COMPANY**NAME**

I	Ignis Therapeutics	Eileen Long
	Immatics	Carsten Reinhardt
	Insmmed	Will Lewis
J	Johnson & Johnson	Michal Preminger
K	Karius	Sivan Bercovici
L	Lundbeck	Keld Flintholm Jorgensen
M	Mahzi	Rob Anstey
	Marshall Wace	Robin David Boldt
	MA7	Michele Brotugno
	MA7	Atila Koc
	Meira GTx	Zandy Forbes
	Meliora Capitol	Thierry Serero
	MGG Capital	Dror Schwartz
	Mineralys	Jon Congleton
	Molecular Partners	Patrick Amstutz
	Molecular Partners	Seth Lewis
	Monte Rosa Therapeutics	John Castle
N	Nature Biotechnology	Melanie Senior
	Neurelis	Craig Chambliss
	Neuron23	Nancy Stagliano
	NiKang Therapeutics	Zhenhai Gao
	Norgine	Peter Stein
	Novartis	Jesus Baena
	Novartis	Markus Werner
	Novartis Venture Fund	Anja Koenig
	Numab Therapeutics	Roland Helfenstein
	Numab Therapeutics	David Urech
	O	Oculis
Odyssey Therapeutics		Gary Glick
OM Pharma		Etienne Jornod
Orano Med		Julien Dodet
OrbiMed		Dina Chaya
OrbiMed		Ashiya Mona
Orna Therapeutics		Brian Shuster
P	Partners Group	Jean Ghabache
	Peel Hunt	Miles Dixon
	Peel Hunt	Markuz Jaffe
	Perspective Therapeutics	Thijs Spoor
	Pharvaris	Wim Souverijns
	PKB Private Bank	Roland Eberhard
	Pureos	Martin Münchbach

COMPANY**NAME**

Q	Quan Capital	Marietta Wu
R	Real Endpoints	Jeffrey Berkowitz
	Roche	Céline Bouquet
	Roche	Marc Christian Buser
	Rock Springs Capital	Mark Bussard
	Rothschild & Co.	Jeremy Wiseman
S	Royalty Pharma	Jim Reddoch
	Sai	Krishna Kanumuri
	Sanofi	Monika Vnuk
	SBTech Global Consulting	Shmulik Berkovich
	Shenzhen Chipscreen Biosciences	Xian-Ping Lu
	Sidley Austin	Mehdi Khodadad
	Sobi	Guido Oelkers
	Sobi	Daniel Rankin
	SR One Capital Management	Iqbal Mufti
	Suvretta Capital Management	Anne Ahl
	Suvretta Capital Management	Kishen Mehta
Swiss Biotech Association	Michael Altorfer	
Swixx Biopharma	Jean-Michel Lespinasse	
Swixx Biopharma	Stuart Swanson	
Syncona	John Tsai	
T	Thermo Fisher Scientific	Michel Lagarde
	Travere Therapeutics	Eric Dube
	Travere Therapeutics	Giovanni Stropoli
	TrueMed Therapeutics	Idan Berkovich
U	UCB	David Flint
	Vascudyne	Claude Richard Amos
	Vemeer Partners	Simon Barrell
V	Venrock	Nimish Shah
	Vicore Pharma	Ahmed Mousa
	Wellington Management	Nilesh Kumar
W	Yaya Capital	Tiago Menezes
	Yaya Capital	Marcus Pratini
	Y-mAbs Therapeutics	Thomas Gad
	Y-mAbs Therapeutics	Michael Rossi
	Ysios Capital	Joël Jean-Mairet
Z	Zymeworks	Lindsey Foulkes
	Zymeworks	Kenneth Galbraith
	Zymeworks	Shrinal Inamdar

PRESENTING COMPANIES

These companies will give each a 15 minute presentation.

abbvie 

abivax 

ADARx
PHARMACEUTICALS 

insmed 

Johnson & Johnson 

KARIUS 

alumis 

argenx 

ALX
ONCOLOGY 

MAHZI
therapeutics 

MEIRAGTx 

MINERALYS 

apharapharma 

ARCUTIS
BIOTHERAPEUTICS 

arrakis
THERAPEUTICS 

MOLECULAR
partners 

Monte Rosa
THERAPEUTICS 

NEURELIS 

NEURON²³ 

NKT 

NUMAB 

astellas 

ATARA BIO 

basilea
PHARMACEUTICA 

ODYSSEY
THERAPEUTICS 

oranomed 

ORNA 

biohaven 

BioInvent 

biomea
FUSION 

PERSPECTIVE
THERAPEUTICS 

re:real
endpoints 

ROYALTY PHARMA 

BIONTECH 

cellanome 

Chemomab
THERAPEUTICS 

sanofi 

微芯生物
CHIPSCREEN 

sobi 

denali 

drenbio 

eGenesis 

TRAVERE
THERAPEUTICS 

TrueMed 

vicore pharma 

方舟健客
Fangzhou Inc. | Stock Code: 06086.HK 


Fore 

IGNIS
翼思生物 

-mAbs
Therapeutics 

zymeworks
MAKING BETTER BIOLOGICS 

LOCATIONS



ZUNFTHAUS ZUR MEISEN

Münsterhof 20
8001 Zurich



Historical house from the middle age, located in the middle of the city directly by the Limmat, in a magnificent building steeped with history from the Middle Ages.

PARK HYATT ZURICH

Beethovenstrasse 21
8002 Zurich



Park Hyatt Zurich is perfectly situated between the picturesque Lake Zurich and the famous Old Town.

RESTAURANT SEEROSE

Seestrasse 493
8038 Zurich



Welcome to Zurich's most beautiful lake shore. Here you'll find a maritime world of its own.